Celine Perez-Decouty

Madrid, MD 28009, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Uncovering the Role of Thrombospodin-1 and Occludin as Potential Prognostic and Diagnostic Biomarkers in Traumatic Brain Injury.

Uncovering the Role of Thrombospodin-1 and Occludin as Potential Prognostic and Diagnostic Biomarkers in Traumatic Brain Injury.

Journal: International journal of molecular sciences

Published: November 13, 2025

Pharmacological evaluation of non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation in traumatic brain injury.

Pharmacological evaluation of non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation in traumatic brain injury.

Journal: British journal of pharmacology

Published: September 25, 2024

Nox4 is involved in acute kidney injury associated to intravascular hemolysis.

Nox4 is involved in acute kidney injury associated to intravascular hemolysis.

Journal: Free radical biology & medicine

Published: September 02, 2024

Redox Regulation of Microglial Inflammatory Response: Fine Control of NLRP3 Inflammasome through Nrf2 and NOX4.

Redox Regulation of Microglial Inflammatory Response: Fine Control of NLRP3 Inflammasome through Nrf2 and NOX4.

Journal: Antioxidants (Basel, Switzerland)

Published: July 03, 2023

m-Terphenylamines, Acting as Selective COX-1 Inhibitors, Block Microglia Inflammatory Response and Exert Neuroprotective Activity.

m-Terphenylamines, Acting as Selective COX-1 Inhibitors, Block Microglia Inflammatory Response and Exert Neuroprotective Activity.

Journal: Molecules (Basel, Switzerland)

Published: June 14, 2023

Activation of NLRP3 Is Required for a Functional and Beneficial Microglia Response after Brain Trauma.

Activation of NLRP3 Is Required for a Functional and Beneficial Microglia Response after Brain Trauma.

Journal: Pharmaceutics

Published: July 04, 2022

Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout.

Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout.

Journal: Journal of medicinal chemistry

Published: April 11, 2022

Serum Amyloid A1/Toll-Like Receptor-4 Axis, an Important Link between Inflammation and Outcome of TBI Patients.

Serum Amyloid A1/Toll-Like Receptor-4 Axis, an Important Link between Inflammation and Outcome of TBI Patients.

Journal: Biomedicines

Published: April 21, 2021

Time-dependent dual effect of NLRP3 inflammasome in brain ischaemia.

Time-dependent dual effect of NLRP3 inflammasome in brain ischaemia.

Journal: British journal of pharmacology

Published: December 18, 2020

Melatonin Reduces NLRP3 Inflammasome Activation by Increasing α7 nAChR-Mediated Autophagic Flux.

Melatonin Reduces NLRP3 Inflammasome Activation by Increasing α7 nAChR-Mediated Autophagic Flux.

Journal: Antioxidants (Basel, Switzerland)

Published: November 26, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026